Want to see CRNX full AI Analyst Report?
CRNX Stock Chart & Stats
$41.00
-$0.61(-1.22%)
At close: 4:00 PM EST
$41.00
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$25.83 - $84.00
Previous CloseN/A
Volume214.21K
Average Volume (3M)5.70M
Market Cap
$8.88B
Enterprise Value$2.54K
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$47.85M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 04, 2026EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.14
Shares Outstanding105,840,230
10 Day Avg. Volume14,528,751
30 Day Avg. Volume5,699,937
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$82.22Price Target Upside100.54% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)-4.83
Revenue Forecast (FY)$68.71M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & RunwayA ~$1.3B cash/investments balance providing runway into 2030 materially reduces near-term financing pressure and gives management flexibility to fund commercial scale-up, multiple pivotal readouts, and regulatory filings. This supports long-term execution on launch and clinical goals without immediate capital raises.
Early Commercial TractionGenerating product revenue and adding new patient forms in an initial commercial launch demonstrates real product-market fit and prescriber uptake. Early paid prescriptions and enrollment growth underpin a reproducible launch model, improve payer engagement, and create a foundation for durable revenue growth as coverage and prescriber adoption expand.
Robust Clinical & Scientific MomentumAn active, multi‑trial pipeline across late‑stage and dose‑escalation programs diversifies clinical risk and extends future commercial optionality. Publications and presentations that bolster efficacy claims strengthen payer discussions and formulary access, supporting sustained long‑term growth potential beyond the initial launch.
Bears Say
High Cash BurnSustained ~-$414M operating cash flow and ~-$420M free cash flow TTM signal a high structural cash burn rate; even with a strong balance sheet, continued elevated spending requires either sustained commercial escalation or financing events. Prolonged burn increases execution risk if launches or readouts underperform expectations.
Large Net Losses & Negative MarginsA near‑half‑billion dollar TTM net loss and deeply negative margins reflect that revenue remains small relative to investment levels. Persistently negative profitability constrains internal capital generation, heightens dependency on balance sheet capital or partners, and lengthens the timeline to self‑sustaining operations absent margin improvement.
Limited Commercial Visibility & Operational BottlenecksNot disclosing form‑to‑paid conversion and related metrics reduces visibility into true adoption and sustainable revenue per enrolled patient. Combined with cited appointment availability constraints and a remaining ~30% reimbursement gap, this opacity complicates forecasting, resource allocation, and the timeline for durable commercial scale.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $25.83 and its highest was $84.00 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $8.88B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Aug 04, 2026 which is in 15 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on May 07, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.19.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 105,840,230 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went down -13.819%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$82.22 (100.54% Upside)
$82.22 (100.54% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 10.6%
Last 30 Days ▼ 10.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
153.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
CRNX Stock 12 Month Forecast
Average Price Target
$82.22
▲(100.54% Upside)
Technical Analysis
Ownership Overview
1.94% Insiders
40.95% Mutual Funds
0.06% Other Institutional Investors
40.51% Public Companies and
Individual Investors